Capital News

Biologics Market Share Will Take A Big Hit In The Coming Years According To New Research Report | Grand View Research, Inc.

 Breaking News
  • No posts were found

Biologics Market Share Will Take A Big Hit In The Coming Years According To New Research Report | Grand View Research, Inc.

April 12
18:26 2021
Biologics Market Share Will Take A Big Hit In The Coming Years According To New Research Report | Grand View Research, Inc.

“Grand View Research, Inc. – Market Research And Consulting.”
The biologics market is expected to continue on a promising growth path in the coming years, as per a study by Grand View Research, owing to sustained development of novel therapies, with these products enabling significant scientific discoveries. The current COVID-19 pandemic is expected to influence the industry advancement in the near future.

The global biologics market size is anticipated to reach USD 399.5 billion by 2025, according to a report by Grand View Research, Inc. The industry is projected to advance at a CAGR of 3.9% over the forecast period. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine is anticipated to fuel market demand in the coming years. Ever-increasing understanding of cell physiology and stress, as well as the factors involved in protein production and heterologous gene expression, have empowered the use of different living factories, which are the prokaryotic and eukaryotic cells. Enhancement of drug functionality through achieving successful protein folding and post-translational modifications is supportive for the overall industry growth. Moreover, rising adoption of biopharmaceuticals over chemically synthesized molecules is expected to propel revenue generation significantly.

The global prevalence of several metabolic disorders that can be treated through the use of biologics is indicated to influence industry demand in the near future. Combination of advanced bioengineering technologies for biopharmaceutical production is expected to boost progress in the pharmaceutical sector. With recent advances in automation, the selection process can be done through a high throughput screening (HTS) system for selection of viable clones. This enables robust production of biopharmaceutical products by obtaining high-producing cell lines. Advances with respect to upstream and downstream processing would directly translate into revenue growth for this market at a larger level. However, development of biosimilars is expected to restrain the growth of the biologics market to a certain extent in the future. Although the regulatory approval pathway for these products is not framed, some drug manufacturers are opting to invest in the development of biobetters. 

Browse full report with Table of Content @ https://www.grandviewresearch.com/industry-analysis/biologics-market

Biologics Market Report Highlights

 The development and manufacture of biologic drugs is a costly process, with these complex proteins being manufactured in living cells. As per IQVIA data from 2017, these drugs represented only 2% of all U.S. prescriptions, but 37% of the net drug spending

With regards to source, the microbial expression systems dominated the biologics market, the systems typically covering E. Coli and yeast. The production of a substantial number of drugs using these products is responsible for the higher market share

In terms of disease, the oncology segment dominated the biologics industry for over a decade, and is expected to sustain its share over the forecast period, owing to introduction of novel biologics with high efficacy coupled with the high prevalence of cancer globally

Substantial sales of biologics in the U.S. can be attributed for the largest share of North American biologics market; on the other hand, Asia Pacific is projected to showcase fastest growth in the coming years

Key players contributing in this market are F Hoffmann La Roche, Samsung Biologics, Celltrion, Pfizer Inc., Amgen, Novo Nordisk A/S, Sanofi, Abbvie Inc., Merck & Co. Inc, Addgene, Johnson & Johnson Services Inc., and Eli Lilly & Company. These participants are investing in hybrid business models through provision of technology and service platforms

The University of Edinburgh & FUJIFILM Diosynth Biotechnologies UK agreed to a partnership in April 2021 for developing cost-effective methods of manufacturing biological drugs. The 5-year research collaboration will make use of the latest analytical tools and engineering biology approaches in this regard

Ask for Sample Pages @ https://www.grandviewresearch.com/industry-analysis/biologics-market/request/rs1

Biologics Market Segmentation

Grand View Research has segmented the biologics market on the basis of source, product, manufacturing, disease category, and region:

Biologics Source Outlook (Revenue, USD Billion, 2014 – 2025)

     Microbial
     Mammalian
     Others

Biologics Product Outlook (Revenue, USD Billion, 2014 – 2025)

     Monoclonal Antibodies
        • By application
             • Diagnostic
                   • Biochemical Analysis
                   • Diagnostic Imaging
             • Therapeutic
                   • Direct MAB Agents
                   • Targeting MAB Agents
             • Protein Purification
             • Others
        • By type
             • Murine
             • Chimeric
             • Humanized
             • Human
             • Others
        • Vaccines
        • Recombinant Proteins
        • Antisense, RNAi, & Molecular Therapy
        • Others

Biologics Manufacturing Outlook (Revenue, USD Billion, 2014 – 2025)

     In-house
     Outsourced

Biologics Disease Category Outlook (Revenue, USD Billion, 2014 – 2025)

     Oncology
        • By Product
             • MABs
             • Vaccines
             • Recombinant Proteins
             • Antisense, RNAi, & Molecular Therapy
             • Others (Certain products under trials related to blood products etc)
     Infectious Diseases
         • By Product
             • MABs
             • Vaccines
             • Recombinant Proteins
             • Antisense, RNAi, & Molecular Therapy
             • Others
     Immunological Disorders
     Cardiovascular Disorders
    Hematological Disorders
     Others

Biologics Regional Outlook (Revenue, USD Billion, 2014 – 2025)

     North America
        • The U.S.
        • Canada
     Europe
        • Germany
        • U.K.
    • Asia Pacific
        • China
        • Japan
    Latin America
        • Brazil
    • Middle East & Africa
        • South Africa

Speak to Analyst @ https://www.grandviewresearch.com/inquiry/602/ibb

About Grand View Research

Grand View Research, Inc. is a market research and consulting company based in India and the US, and headquartered in San Francisco. The organization offers syndicated and customized research reports in 46 industries across key regional markets, such as the US, Canada, Latin America, Europe, and Asia Pacific, among others.

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1888202951
Address:Grand View Research, Inc. 201 Spear Street 1100 San Francisco, CA 94105, United States
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/biologics-market


Warning: count(): Parameter must be an array or an object that implements Countable in /home/capitalnews/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share